Precision BioSciences, Inc. (DTIL)
NASDAQ: DTIL · Real-Time Price · USD
3.830
-0.050 (-1.29%)
Feb 4, 2026, 4:00 PM EST - Market closed
Precision BioSciences Employees
Precision BioSciences had 67 employees as of September 30, 2025. The number of employees decreased by 41 or -37.96% compared to the same quarter last year.
Employees
67
Change
-41
Growth
-37.96%
Revenue / Employee
$10,418
Profits / Employee
-$1,247,791
Market Cap
92.19M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2025 | 67 | -41 | -37.96% |
| Jun 30, 2025 | 102 | -8 | -7.27% |
| Mar 31, 2025 | 107 | -2 | -1.83% |
| Dec 31, 2024 | 108 | -1 | -0.92% |
| Sep 30, 2024 | 108 | -7 | -6.09% |
| Jun 30, 2024 | 110 | -82 | -42.71% |
| Mar 31, 2024 | 109 | -88 | -44.67% |
| Dec 31, 2023 | 109 | -89 | -44.95% |
| Sep 30, 2023 | 115 | -79 | -40.72% |
| Jun 30, 2023 | 192 | 0 | - |
| Mar 31, 2023 | 197 | 7 | 3.68% |
| Dec 31, 2022 | 198 | 0 | - |
| Sep 30, 2022 | 194 | -32 | -14.16% |
| Jun 30, 2022 | 192 | -44 | -18.64% |
| Mar 31, 2022 | 190 | -47 | -19.83% |
| Dec 31, 2021 | 198 | -33 | -14.29% |
| Sep 30, 2021 | 226 | 3 | 1.35% |
| Jun 30, 2021 | 236 | 16 | 7.27% |
| Mar 31, 2021 | 237 | 12 | 5.33% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Agenus | 316 |
| Champions Oncology | 213 |
| Fortress Biotech | 101 |
| aTyr Pharma | 65 |
| Pyxis Oncology | 44 |
| ALX Oncology Holdings | 44 |
| Equillium | 35 |
| Cassava Sciences | 30 |
DTIL News
- 24 days ago - Precision BioSciences Sets Strategic Priorities for 2026 Focused on Continued Advancement of Clinical-Stage Programs PBGENE-HBV for Chronic Hepatitis B and PBGENE-DMD for Duchenne Muscular Dystrophy - Business Wire
- 5 weeks ago - Precision BioSciences: Potential Proof-Of-Concept Data For HBV Cure In 2026 - Seeking Alpha
- 6 weeks ago - Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 2 months ago - Precision Biosciences: Still Swinging And Finally Drawing Blood - Seeking Alpha
- 2 months ago - Precision BioSciences Announces Presentation of Clinical Data from the ELIMINATE-B Trial at HEP-DART 2025 - Business Wire
- 3 months ago - Precision BioSciences, Inc. (DTIL) Discusses ARCUS Platform Progress and ELIMINATE-B Clinical Trial Update for Chronic Hepatitis B Transcript - Seeking Alpha
- 3 months ago - Precision BioSciences Announces $75 Million Offering of Common Stock, Pre-Funded Warrants and Warrants - Business Wire
- 3 months ago - Precision BioSciences Presents Late-Breaking Phase 1 PBGENE-HBV Data at AASLD The Liver Meeting® Showing Safety, Tolerability and Cumulative, Dose-Dependent Antiviral Activity in First Three Cohorts - Business Wire